Urine DNA for monitoring chemoradiotherapy response in muscle-invasive bladder cancer: a pilot study

BJU Int. 2022 Jan;129(1):32-34. doi: 10.1111/bju.15589. Epub 2021 Sep 20.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Biomarkers, Tumor / urine
  • Cetuximab / administration & dosage
  • Chemoradiotherapy
  • Clinical Trials, Phase I as Topic
  • Clinical Trials, Phase II as Topic
  • DNA, Neoplasm / analysis
  • DNA, Neoplasm / urine*
  • Fluorouracil / administration & dosage
  • Humans
  • Liquid Biopsy
  • Mitomycin / administration & dosage
  • Muscle, Smooth / pathology
  • Mutation
  • Neoplasm Invasiveness
  • Neoplasm Recurrence, Local / genetics
  • Neoplasm Recurrence, Local / urine*
  • Pilot Projects
  • Receptor, Fibroblast Growth Factor, Type 3 / genetics
  • Sequence Analysis, DNA
  • Telomerase / genetics
  • Treatment Outcome
  • Tumor Suppressor Protein p53 / genetics
  • Urinary Bladder Neoplasms / genetics
  • Urinary Bladder Neoplasms / pathology
  • Urinary Bladder Neoplasms / therapy*
  • Urinary Bladder Neoplasms / urine*

Substances

  • Biomarkers, Tumor
  • DNA, Neoplasm
  • TP53 protein, human
  • Tumor Suppressor Protein p53
  • Mitomycin
  • FGFR3 protein, human
  • Receptor, Fibroblast Growth Factor, Type 3
  • TERT protein, human
  • Telomerase
  • Cetuximab
  • Fluorouracil